AU2008240704A1 - Heterocyclic compounds with affinity to muscarinic receptors - Google Patents

Heterocyclic compounds with affinity to muscarinic receptors Download PDF

Info

Publication number
AU2008240704A1
AU2008240704A1 AU2008240704A AU2008240704A AU2008240704A1 AU 2008240704 A1 AU2008240704 A1 AU 2008240704A1 AU 2008240704 A AU2008240704 A AU 2008240704A AU 2008240704 A AU2008240704 A AU 2008240704A AU 2008240704 A1 AU2008240704 A1 AU 2008240704A1
Authority
AU
Australia
Prior art keywords
pyrazol
compound
tetrahydro
methylpyridine
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008240704A
Other languages
English (en)
Inventor
Hein K.A.C. Coolen
Cornelis G. Kruse
Axel Stoit
Louise heir of Reinders Jan H. Terwel (deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Publication of AU2008240704A1 publication Critical patent/AU2008240704A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
AU2008240704A 2007-04-24 2008-04-23 Heterocyclic compounds with affinity to muscarinic receptors Abandoned AU2008240704A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91358407P 2007-04-24 2007-04-24
US60/913,584 2007-04-24
EP07106814.2 2007-04-24
EP07106814 2007-04-24
PCT/EP2008/054897 WO2008129054A2 (en) 2007-04-24 2008-04-23 Heterocyclic compounds with affinity to muscarinic receptors

Publications (1)

Publication Number Publication Date
AU2008240704A1 true AU2008240704A1 (en) 2008-10-30

Family

ID=38510408

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008240704A Abandoned AU2008240704A1 (en) 2007-04-24 2008-04-23 Heterocyclic compounds with affinity to muscarinic receptors

Country Status (8)

Country Link
EP (1) EP2150543A2 (zh)
JP (1) JP2010525020A (zh)
CN (1) CN101939311A (zh)
AU (1) AU2008240704A1 (zh)
CA (1) CA2682994A1 (zh)
MX (1) MX2009011499A (zh)
RU (1) RU2446166C2 (zh)
WO (1) WO2008129054A2 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084473B2 (en) 2007-04-24 2011-12-27 Solvay Pharmaceuticals B.V. Heterocyclic compounds with affinity to muscarinic receptors
EP2427432A2 (en) * 2009-05-07 2012-03-14 Torrent Pharmaceuticals Limited Novel heterocyclic compounds
EP2593447B1 (de) 2010-07-15 2016-08-17 Bayer Intellectual Property GmbH 3-pyridyl-heteroarylcarboxamidverbindungen als schädlingsbekämpfungsmittel
CN104640850A (zh) 2012-10-26 2015-05-20 霍夫曼-拉罗奇有限公司 3,4-二取代的1h-吡唑和4,5-二取代的噻唑的syk抑制剂
AR121893A1 (es) 2020-04-22 2022-07-20 Sumitomo Chemical Co Compuesto de fenilo y método para controlar enfermedades vegetales

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83275A (en) * 1986-09-08 1994-02-27 Novo Nordisk As Compounds 1,2, 4-Oxadiazolyl Pipridine Transformed, their preparation and pharmaceutical preparations containing them
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
IL88156A (en) * 1987-11-13 1997-02-18 Novo Nordisk As Azacyclic compounds their preparation and pharmaceutical compositions containing them
CA2332957A1 (en) * 1998-06-05 1999-12-09 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
EP1438309A1 (en) * 2001-10-17 2004-07-21 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
US20100160324A1 (en) * 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases

Also Published As

Publication number Publication date
CN101939311A (zh) 2011-01-05
WO2008129054A2 (en) 2008-10-30
RU2009143353A (ru) 2011-05-27
RU2446166C2 (ru) 2012-03-27
CA2682994A1 (en) 2008-10-30
MX2009011499A (es) 2009-11-09
WO2008129054A3 (en) 2009-02-05
EP2150543A2 (en) 2010-02-10
JP2010525020A (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
EP3083618B1 (en) Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CA2627839C (en) Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US5883102A (en) Pharmaceutically active compounds
JP5433418B2 (ja) 多環式化合物
EP2867236B1 (en) Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
RU2100357C1 (ru) Гетероариламины или их фармацевтически приемлемые соли и фармацевтическая композиция на их основе
JP6305510B2 (ja) ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾロピリドン
AU2006298164A1 (en) Novel fused pyrrole derivative
AU2008235456A1 (en) [2, 6] naphthyridines useful as protein kinase inhibitors
AU2021282596A1 (en) Inhibitors of fibroblast growth factor receptor kinases
AU2008240704A1 (en) Heterocyclic compounds with affinity to muscarinic receptors
KR20010094731A (ko) 이미다졸 화합물 및 그의 의약 용도
AU2021285974A1 (en) Inhibitors of fibroblast growth factor receptor kinases
CN114727992A (zh) 作为Kv1.3钾Shaker通道阻滞剂的芳基亚甲基芳族化合物
JP2564714B2 (ja) １−（置換ピリジニルアミノ）−１ｈ−インドール−５−イル置換カルバメート
US8735388B2 (en) Heterocyclic compounds with affinity to muscarinic receptors
TW202330538A (zh) 螺環化合物
WO2018109271A1 (en) New bromodomain inhibitors
TW202140499A (zh) 巨環ｒｉｐ２－激酶抑制劑
CN114761399B (zh) 作为布鲁顿酪氨酸激酶抑制剂的咪唑甲酰胺衍生物
JP2023514364A (ja) Ｍｃｌ－１の阻害剤としての大環状インドール誘導体
JP2022531780A (ja) Ｔｄｇ活性を阻害する化合物
UA113436C2 (xx) 4-(ЗАМІЩЕНІ АМІНО)-7H-ПІРОЛО[2,3-d]ПІРИМІДИНИ ЯК ІНГІБІТОРИ LRRK2

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application